Within 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
Aspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) each < 3×ULN; however, ALT, AST, and TBILI each ? 5×ULN is acceptable if the elevation is considered due to PTLD involvement of the liver.
Alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × the upper limit of normal (ULN) (=< 5 × ULN if considered due to primary or metastatic liver involvement)
Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma - then =< 5 x ULN obtained =< 14 days prior to registration
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ? 3 upper limit of normal (ULN). In cases with liver involvement ALT/ AST ? 5× ULN.
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 10 upper limit of normal (ULN) (unless elevated ALT/AST is attributed to leukemia or lymphoma involvement of the liver, in which case this criterion will be waived and not disqualify a patient)
Aspartate and alanine aminotransferase (AST and ALT) =< 2.5 x ULN; =< 5.0 x ULN if there is liver involvement secondary to tumor
Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x ULN for patients without tumor involvement of the liver or >5 x ULN for patients with tumor involvement of the liver.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x the upper limit of normal (ULN), if no liver involvement or ?5 x ULN with liver involvement
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 x the ULN for the reference lab (=< 5 x the ULN if there is evidence of hepatic involvement by malignant disease)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception: patients with liver involvement: AST and/or ALT =< 5 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless due to liver involvement)
Alanine aminotransferase (ALT) =< 2.5 x ULN unless demonstrated lymphoma involvement of the liver, performed within 14 days prior to day 1 of protocol therapy
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ? 5 x ULN
STUDY TREATMENT: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 × ULN within 14 days prior to the first study treatment with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 × ULN.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3x the institutional ULN, except for people with liver involvement by their lymphoma, who may be included if AST/ALT ? 5x the institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) =< 2 x ULN (=< 5 x ULN for patients with liver involvement)
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 10 upper limit of normal (ULN) (unless elevated ALT/AST is associated with leukemia or lymphoma involvement of the liver, in which case this criterion will be waived and not disqualify a patient)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3x ULN unless considered due to leukemic involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the exception that patients with liver involvement: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN or, in the case of liver involvement by the primary disease AST/ALT =< 5 x ULN
Within 14 days prior to cycle 1 day 1 of treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN (5.0 x ULN if liver involvement)
Within 14 days prior to cycle 1 day 1 of treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN (5.0 x ULN if liver involvement)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if related to leukemic involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
FULL STUDY INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer)
To be performed within 10 business days prior to day 1: Alanine aminotransferase (ALT) =< 3 x ULN unless demonstrated Hodgkin lymphoma involvement of the liver
Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) if no liver involvement or =< 5 x the ULN if documented liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN), except for people with liver involvement by their lymphoma, who may be included if AST/ALT =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
Liver function abnormality as defined by total bilirubin >1.5 × ULN or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >2.5 × ULN (except for subjects with liver involvement, who can have AST/ALT >5 × ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN if patients have liver involvement with MM)
Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the ULN unless considered due to organ leukemic involvement
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or < 5 x ULN if related to leukemic involvement
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 X ULN, or for subjects with liver involvement AST and/or ALT > 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT ) < 2.5 x the upper limits of institutional normal (=< 5 x ULN for patients with liver involvement of leukemia)
Alanine and aspartate transaminases (ALT and AST) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 x ULN if due to lymphoma involvement, without use of growth factor support for 1 week
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x the upper limits of institutional normal (=< 5 x ULN for patients with suspected liver involvement of leukemia)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if there is evidence of hepatic involvement by malignant disease)
Alanine aminotransferase (ALT) and aspartate aminotransferease (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x the ULN if no liver involvement, or =< 5 x the ULN with liver involvement
Aspartate aminotransferases (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN (unless elevated due to secondary lymphomatous involvement of the liver)
Total bilirubin ?1.5 × the upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN.
Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma – then =< 5 x ULN
SUB-PROTOCOL AIM A: Aspartate transaminase (AST); alanine aminotransferase (ALT) =< 1.5 x ULN; NOTE: if subject has tumor involvement in the liver =< 5 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x ULN, or =< 5.0 x ULN for patients with documented hepatic involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 if due to lymphoma involvement
Aspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN (=< 5 x ULN for patients with liver involvement)
Total bilirubin 1.5 × the upper limit of institutional normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN are acceptable.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) obtained =<14 days prior to randomization
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (less than or equal to 5 x upper limit of normal for patients with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 x ULN if no liver involvement or =< 4 x the ULN if known liver involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 times upper limit of normal (ULN); (for patients with liver involvement: AST and ALT =< 2.5 ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); aspartate aminotransferase measurement (AST) and alanine aminotransferase measurement (ALT) ? 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT ? 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN if no liver involvement, or =< 5 X ULN with liver involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 ULN (obtained within 14 days prior to the first study treatment [course 1, day 1]) with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
Alanine aminotransferase and aspartate aminotransferase < 2.5 of the ULN (< 5 x of ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with hepatic involvement with tumor)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) =< 3 x ULN for the institution (=< 5 x ULN is acceptable if liver has tumor involvement)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, unless due to liver involvement with lymphoma
Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) levels must be =< 2.5 x ULN, or =< 5 X ULN for patients with liver involvement by lymphoma
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5.0 ULN if hepatic involvement is present as determined by the investigator
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 X institutional ULN (unless demonstrated Hodgkin lymphoma involvement of the liver)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 times the ULN (>= 5 x ULN for patients with liver involvement)
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 the upper limit of normal (ULN); < 5 ULN if there is liver involvement secondary to the tumor
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN), except for people with liver involvement by their lymphoma, who may be included if AST/ALT =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x ULN (5 x ULN for those with lymphoma involvement of the liver)
Alanine transaminase (alanine aminotransferase [ALT]) =< 2 x upper normal limit (ULN) (in the expansion cohort, patients with known liver involvement may have ALT =< 5 x ULN); aspartate aminotransferase (AST) =< 2 x ULN (in the expansion cohort, patients with known liver involvement may have AST =< 5 x ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN in the absence of known metastatic involvement of the liver or AST and ALT =< 5.0 x ULN if there is metastatic liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x ULN if no liver involvement or ?5 x ULN with liver involvement.
